Subtype-specific regulatory network rewiring in acute myeloid leukemia.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
01 2019
Historique:
received: 02 02 2018
accepted: 02 10 2018
pubmed: 14 11 2018
medline: 25 4 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of alterations in transcription factors, epigenetic regulators and signaling molecules. To determine how different mutant regulators establish AML subtype-specific transcriptional networks, we performed a comprehensive global analysis of cis-regulatory element activity and interaction, transcription factor occupancy and gene expression patterns in purified leukemic blast cells. Here, we focused on specific subgroups of subjects carrying mutations in genes encoding transcription factors (RUNX1, CEBPα), signaling molecules (FTL3-ITD, RAS) and the nuclear protein NPM1). Integrated analysis of these data demonstrates that each mutant regulator establishes a specific transcriptional and signaling network unrelated to that seen in normal cells, sustaining the expression of unique sets of genes required for AML growth and maintenance.

Identifiants

pubmed: 30420649
doi: 10.1038/s41588-018-0270-1
pii: 10.1038/s41588-018-0270-1
pmc: PMC6330064
mid: EMS79897
doi:

Substances chimiques

NPM1 protein, human 0
Transcription Factors 0
Nucleophosmin 117896-08-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-162

Subventions

Organisme : Medical Research Council
ID : MR/M009157/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P019609/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
doi: 10.1056/NEJMoa1301689
Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
pubmed: 27276561 pmcid: 4979995 doi: 10.1056/NEJMoa1516192
Bonifer, C. & Cockerill, P. N. Chromatin structure profiling identifies crucial regulators of tumor maintenance. Trends Cancer 1, 157–160 (2015).
pubmed: 28741472 doi: 10.1016/j.trecan.2015.10.003
Rosenbauer, F. & Tenen, D. G. Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 7, 105–117 (2007).
pubmed: 17259967 doi: 10.1038/nri2024
Cockerill, P. N. Receptor signaling directs global recruitment of pre-existing transcription factors to inducible elements. Yale J. Biol. Med. 89, 591–596 (2016).
pubmed: 28018147 pmcid: 5168834
Ward, A. F., Braun, B. S. & Shannon, K. M. Targeting oncogenic Ras signaling in hematologic malignancies. Blood 120, 3397–3406 (2012).
pubmed: 22898602 pmcid: 3482854 doi: 10.1182/blood-2012-05-378596
Parikh, C., Subrahmanyam, R. & Ren, R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 108, 2349–2357 (2006).
pubmed: 16763213 pmcid: 1895567 doi: 10.1182/blood-2004-08-009498
Masson, K. & Ronnstrand, L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 21, 1717–1726 (2009).
pubmed: 19540337 doi: 10.1016/j.cellsig.2009.06.002
Gerloff, D. et al. NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia 29, 535–547 (2015).
pubmed: 25092144 doi: 10.1038/leu.2014.231
Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548–2553 (2014).
pubmed: 24550281 doi: 10.1073/pnas.1324297111 pmcid: 3932921
Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).
pubmed: 24522528 pmcid: 4991939 doi: 10.1038/nature13038
Di Croce, L. & Helin, K. Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol. 20, 1147–1155 (2013).
pubmed: 24096405 doi: 10.1038/nsmb.2669
Broske, A. M. et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet. 41, 1207–1215 (2009).
pubmed: 19801979 doi: 10.1038/ng.463
Bonifer, C. & Bowen, D. T. Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine. Expert Rev. Mol. Med. 12, e6 (2010).
pubmed: 20152067 doi: 10.1017/S1462399410001377
Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23–31 (2012).
doi: 10.1038/ng.1009
Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).
pubmed: 21057493 pmcid: 3003755 doi: 10.1038/nature09586
Shih, A. H., Abdel-Wahab, O., Patel, J. P. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599–612 (2012).
pubmed: 22898539 doi: 10.1038/nrc3343
Goode, D. K. et al. Dynamic gene regulatory networks drive hematopoietic specification and differentiation. Dev. Cell 36, 572–587 (2016).
pubmed: 26923725 pmcid: 4780867 doi: 10.1016/j.devcel.2016.01.024
Obier, N. & Bonifer, C. Chromatin programming by developmentally regulated transcription factors: lessons from the study of haematopoietic stem cell specification and differentiation. FEBS Lett. 590, 4105–4115 (2016).
pubmed: 27497427 doi: 10.1002/1873-3468.12343
Wilson, N. K. et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7, 532–544 (2010).
pubmed: 20887958 doi: 10.1016/j.stem.2010.07.016
Rubin, A. J. et al. Lineage-specific dynamic and pre-established enhancer-promoter contacts cooperate in terminal differentiation. Nat. Genet. 49, 1522–1528 (2017).
pubmed: 28805829 pmcid: 5715812 doi: 10.1038/ng.3935
Ptasinska, A. et al. Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal. Cell Rep. 8, 1974–1988 (2014).
pubmed: 25242324 pmcid: 4487811 doi: 10.1016/j.celrep.2014.08.024
Loke, J. et al. RUNX1-ETO and RUNX1-EVI1 differentially reprogram the chromatin landscape in t(8;21) and t(3;21) AML. Cell Rep. 19, 1654–1668 (2017).
pubmed: 28538183 pmcid: 5457485 doi: 10.1016/j.celrep.2017.05.005
Cauchy, P. et al. Chronic FLT3-ITD signaling in acute myeloid leukemia is connected to a specific chromatin signature. Cell Rep. 12, 821–836 (2015).
pubmed: 26212328 pmcid: 4726916 doi: 10.1016/j.celrep.2015.06.069
Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193–1203 (2016).
pubmed: 27526324 pmcid: 5042844 doi: 10.1038/ng.3646
McKeown, M. R. et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARalpha dependency targetable by SY-1425, a potent and selective RARalpha agonist. Cancer Discov. 7, 1136–1153 (2017).
pubmed: 28729405 pmcid: 5962349 doi: 10.1158/2159-8290.CD-17-0399
Martens, J. H. et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 120, 4038–4048 (2012).
pubmed: 22983443 pmcid: 3496958 doi: 10.1182/blood-2012-05-429050
Pulikkan, J. A., Tenen, D. G. & Behre, G. C/EBPalpha deregulation as a paradigm for leukemogenesis. Leukemia 31, 2279–2285 (2017).
pubmed: 28720765 doi: 10.1038/leu.2017.229 pmcid: 8197657
Piper, J. et al. Wellington: a novel method for the accurate identification of digital genomic footprints from DNase-seq data. Nucleic Acids Res. 41, e201 (2013).
pubmed: 24071585 pmcid: 3834841 doi: 10.1093/nar/gkt850
Ptasinska, A. et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 26, 1829–1841 (2012).
pubmed: 22343733 pmcid: 3419980 doi: 10.1038/leu.2012.49
Mandoli, A. et al. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. Leukemia 28, 770–778 (2014).
pubmed: 24002588 doi: 10.1038/leu.2013.257
Dunne, J. et al. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. Cancer Res. 70, 3985–3995 (2010).
pubmed: 20460523 pmcid: 2883733 doi: 10.1158/0008-5472.CAN-09-3604
Dekker, J., Rippe, K., Dekker, M. & Kleckner, N. Capturing chromosome conformation. Science 295, 1306–1311 (2002).
pubmed: 11847345 doi: 10.1126/science.1067799
Mifsud, B. et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat. Genet. 47, 598–606 (2015).
pubmed: 25938943 doi: 10.1038/ng.3286
Chasman, D. & Roy, S. Inference of cell type specific regulatory networks on mammalian lineages. Curr. Opin. Syst. Biol. 2, 130–139 (2017).
pubmed: 29082337 pmcid: 5656272 doi: 10.1016/j.coisb.2017.04.001
Neph, S. et al. Circuitry and dynamics of human transcription factor regulatory networks. Cell 150, 1274–1286 (2012).
pubmed: 22959076 pmcid: 3679407 doi: 10.1016/j.cell.2012.04.040
Lin, S. et al. A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program. Blood 130, 1213–1222 (2017).
pubmed: 28710059 pmcid: 5606002 doi: 10.1182/blood-2016-11-750976
O’Connor, C. et al. Nfix expression critically modulates early B lymphopoiesis and myelopoiesis. PLoS One 10, e0120102 (2015).
pubmed: 25780920 pmcid: 4363787 doi: 10.1371/journal.pone.0120102
Somerville, T. D. et al. Frequent derepression of the mesenchymal transcription factor gene FOXC1 in acute myeloid leukemia. Cancer Cell 28, 329–342 (2015).
pubmed: 26373280 doi: 10.1016/j.ccell.2015.07.017
Olive, M. et al. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J. Biol. Chem. 272, 18586–18594 (1997).
pubmed: 9228025 doi: 10.1074/jbc.272.30.18586
Obier, N. et al. Cooperative binding of AP-1 and TEAD4 modulates the balance between vascular smooth muscle and hemogenic cell fate. Development 143, 4324–4340 (2016).
pubmed: 27802171 pmcid: 5201045
Verhaak, R. G. W. et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131–134 (2009).
pubmed: 18838472 doi: 10.3324/haematol.13299
Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010).
pubmed: 20060365 pmcid: 3008568 doi: 10.1016/j.ccr.2009.11.020
Lin, S., Mulloy, J. C. & Goyama, S. RUNX1-ETO leukemia. Adv. Exp. Med. Biol. 962, 151–173 (2017).
pubmed: 28299657 doi: 10.1007/978-981-10-3233-2_11
Goyama, S. et al. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia 30, 728–739 (2016).
pubmed: 26449661 doi: 10.1038/leu.2015.275
Sun, X. J. et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature 500, 93–97 (2013).
pubmed: 23812588 pmcid: 3732535 doi: 10.1038/nature12287
Essig, A., Duque-Afonso, J., Schwemmers, S., Pahl, H. L. & Lubbert, M. The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leuk. Res. 38, 340–345 (2014).
pubmed: 24456692 doi: 10.1016/j.leukres.2013.12.014
Trop-Steinberg, S. & Azar, Y. AP-1 expression and its clinical relevance in immune disorders and cancer. Am. J. Med. Sci. 353, 474–483 (2017).
pubmed: 28502334 doi: 10.1016/j.amjms.2017.01.019
Martinez-Soria, N. et al. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell 34, 626–642.e8 (2018).
pubmed: 30300583 pmcid: 6179967 doi: 10.1016/j.ccell.2018.08.015
Kesarwani, M. et al. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat. Med. 23, 472–482 (2017).
pubmed: 28319094 pmcid: 5424814 doi: 10.1038/nm.4310
Faber, Z. J. et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat. Genet. 48, 1551–1556 (2016).
pubmed: 27798625 pmcid: 5508996 doi: 10.1038/ng.3709
Levis, M. et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117, 3294–3301 (2011).
pubmed: 21270442 pmcid: 3069671 doi: 10.1182/blood-2010-08-301796
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
pubmed: 21478889 pmcid: 3083463 doi: 10.1038/ng.806
van Gosliga, D. et al. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp. Hematol. 35, 1538–1549 (2007).
pubmed: 17889721 doi: 10.1016/j.exphem.2007.07.001
Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral “gene ontology” (LeGO) vectors for functional gene analysis. Mol. Ther. 16, 698–706 (2008).
pubmed: 18362927 doi: 10.1038/mt.2008.6
Mostoslavsky, G. et al. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol. Ther. 11, 932–940 (2005).
pubmed: 15922964 doi: 10.1016/j.ymthe.2005.01.005
Bert, A. G., Johnson, B. V., Baxter, E. W. & Cockerill, P. N. A modular enhancer is differentially regulated by GATA and NFAT elements that direct different tissue-specific patterns of nucleosome positioning and inducible chromatin remodeling. Mol. Cell. Biol. 27, 2870–2885 (2007).
pubmed: 17283044 pmcid: 1899937 doi: 10.1128/MCB.02323-06
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
pubmed: 22388286 pmcid: 3322381 doi: 10.1038/nmeth.1923
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635 pubmed: 23104886
Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat. Biotechnol. 31, 46–53 (2013).
pubmed: 23222703 doi: 10.1038/nbt.2450
Wingett, S. et al. HiCUP: pipeline for mapping and processing Hi-Cdata. F1000Res. 4, 1310 (2015).
pubmed: 26835000 pmcid: 4706059 doi: 10.12688/f1000research.7334.1
Mifsud, B. et al. GOTHiC, a probabilistic model to resolve complex biases and to identify real interactions in Hi-C data. PLoS One 12, e0174744 (2017).
pubmed: 28379994 pmcid: 5381888 doi: 10.1371/journal.pone.0174744
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
pubmed: 20513432 pmcid: 2898526 doi: 10.1016/j.molcel.2010.05.004
Zhang, H. M. et al. AnimalTFDB: a comprehensive animal transcription factor database. Nucleic Acids Res. 40, D144–D149 (2012).
pubmed: 22080564 doi: 10.1093/nar/gkr965

Auteurs

Salam A Assi (SA)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Maria Rosaria Imperato (MR)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Daniel J L Coleman (DJL)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Anna Pickin (A)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Sandeep Potluri (S)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Anetta Ptasinska (A)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Paulynn Suyin Chin (PS)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Helen Blair (H)

Northern Institute for Cancer Research, University of Newcastle, Newcastle, UK.

Pierre Cauchy (P)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Sally R James (SR)

Section of Experimental Haematology, Leeds Institute for Molecular Medicine, University of Leeds, Leeds, UK.

Joaquin Zacarias-Cabeza (J)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

L Niall Gilding (LN)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Andrew Beggs (A)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Sam Clokie (S)

West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.

Justin C Loke (JC)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Phil Jenkin (P)

CMT Laboratory NHS Blood & Transplant, Edgbaston, Birmingham, UK.

Ash Uddin (A)

CMT Laboratory NHS Blood & Transplant, Edgbaston, Birmingham, UK.

Ruud Delwel (R)

Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Oncode Institute, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.

Stephen J Richards (SJ)

Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.

Manoj Raghavan (M)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.

Michael J Griffiths (MJ)

West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.

Olaf Heidenreich (O)

Northern Institute for Cancer Research, University of Newcastle, Newcastle, UK.
Princess Maxima Centrum for Pediatric Oncology, Utrecht, The Netherlands.

Peter N Cockerill (PN)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. p.n.cockerill@bham.ac.uk.

Constanze Bonifer (C)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. c.bonifer@bham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH